Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
about
The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic CancerSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinomaAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyGemcitabine eliminates double minute chromosomes from human ovarian cancer cellsUbiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabineA phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotiniInfluence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Evolution of systemic therapy for advanced pancreatic cancer.Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinomaERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.Lung cancer: Biology and treatment options.Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancerEx vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancerPrognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways.Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.Resistance to chemotherapy in cancer: a complex and integrated cellular response.Treatment of pancreatic cancer: what can we really predict today?Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
P2860
Q26775135-2D9D4F45-F07B-4C1B-AE8F-28BE17C8AF74Q27021716-FF53E804-A6B9-4F02-AC7E-9DA0697299ADQ28066268-B39D5FE8-9835-4BE2-9AD8-60367FC85D7AQ28308112-21D049F2-8516-4EC7-86DC-6372C346E332Q28484288-17E3E251-7106-4105-AB27-433B83057FF9Q28535582-7F78F0C2-C694-4A60-806A-1639E00DA9F9Q28540690-47244A7D-91C0-4D9E-97CC-A6B863DD2707Q33394505-13652994-6100-4923-99A0-FF41A874A1EBQ33394594-4D23358F-9EC4-408D-BE60-79C52EFEA458Q33416585-1D2AF522-8A59-45DE-A407-2F988EBA1337Q33442358-F591B019-26C3-4B43-8AD3-2F0B3DD86E69Q33557413-C0857348-DEE7-40A3-8973-8B503FBCC7EAQ33684978-33F38EAD-853E-4B9B-A1E8-A251BC42E37DQ33719099-4690B9D1-2FCD-4631-9F65-0E8601FCCCF8Q33914197-0B7810CD-939E-4250-BCC6-DAC7A5DE744DQ34177223-7E6EF26D-5087-40E6-AB32-4D03CD14583DQ34205171-5921B300-7736-4445-8744-0E67FE5D53FBQ34585992-90C93953-1E44-4E82-BF19-E284418F784EQ34618606-B28F27F8-6376-4143-A421-C855BCF727B6Q34625514-4D88DCF9-CF20-4406-B203-F60EDC64E6C1Q34756239-B10236A9-ABB0-4D1D-A847-A5CC0CC04ED5Q34906454-99E62C6E-1C2D-4D64-86AA-8667695F1B81Q34957154-1BD9BC6C-96B7-4A5F-BDB7-AFBFCF6E0A33Q35610203-113BF054-19C9-41FB-B1DC-E6385D26EB1AQ35866655-8F68019D-F183-45A9-84AB-FCD46F9A6D4EQ36328370-674863C1-2D7C-4B63-A532-31355DC44696Q36450022-A2FDC946-5D92-45C6-8868-05B61A5347D1Q36553206-19EB9FB7-FD30-4FFD-A9FB-07ABEF7044F9Q36589778-40FC74E9-577A-446B-A374-491F003E081BQ36775333-E5B132F2-973D-4022-91FB-4744ED2AFB8EQ36859193-63AF618F-B80B-4AE8-B578-CDCE94178727Q36893162-57FA5B9C-6870-40E0-83CA-EE2539643238Q36919830-50864D9A-2F19-4129-9135-3ACCF31A51F0Q36928958-BB362BDE-6DB9-4F0D-8BB4-9FAFE35B8BD0Q36931187-8D7B8EB9-A955-4D61-8820-57B93C016CE8Q36962474-03F8C0A3-484B-4E96-A3DB-B61606A51C1EQ37040632-CFF94613-58CA-4F6B-9F74-C897C84420D4Q37079652-5B8A50E8-3C1E-4C51-B3F8-341131DA976EQ37129815-863600BC-CB89-4E57-AE95-C1FCDEFF9CCFQ37183598-7A72429A-B836-49ED-8A9E-5798FF34D72A
P2860
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Involvement of ribonucleotide ...... ce of human pancreatic cancer.
@en
type
label
Involvement of ribonucleotide ...... ce of human pancreatic cancer.
@en
prefLabel
Involvement of ribonucleotide ...... ce of human pancreatic cancer.
@en
P2093
P356
P1476
Involvement of ribonucleotide ...... ce of human pancreatic cancer.
@en
P2093
Atsushi Miyamoto
Hiroaki Nagano
Ichiro Takemasa
Jiro Okami
Keizo Dono
Koji Umeshita
Makoto Yamasaki
Masanori Tsujie
Masato Sakon
Morito Monden
P304
P356
10.1002/IJC.22390
P577
2007-03-01T00:00:00Z